

Inventor(s): Klagsbrun M., et al. Group: 1642
Serial No.: 09/579,420 Examiner: Nickol, Gary B.
Filed: May 25, 2000
FOR: PEPTIDE ANTAGONISTS OF VASCULAR ENDOTHELIAL GROWTH FACTOR



These derivatives were prepared to contain the first cysteine residue of exon 8 at the C
termini to keep an even number of cysteine residue as is shown in SEQ ID NO: 1.

RECEIVED

IN THE CLAIMS

JUN 25 2002

Please amend claims 1 and 4 as follows:

TECH CENTER 1600/2900

- B³
1. (AMENDED) An isolated polypeptide having a portion of SEQ ID NO:1 having
VEGF antagonist activity, wherein said portion includes amino acids 22-44 of SEQ ID NO:1.
4. (AMENDED) A pharmaceutical composition comprising a polypeptide of claim 1 and
a pharmaceutically acceptable carrier.

COPY OF PAPERS
ORIGINALLY FILED

REMARKS

Applicants have amended the specification to reflect the priority status of the present
application, as suggested by the Examiner.

Applicants have also amended specification on page 10, lines 7-8, by adding a sequence
identifier to properly disclose respective amino acid sequences and to comply with the
requirements of 37 CFR 1.821 through 1.825.

Claims 1, 4-6 are pending in the application. Claims 1 and 4 have been amended. The
basis for the amendment to claim 1 can be found on page 5, lines 28-29 of the specification. No
new matter was added by virtue of the aforementioned amendments, and their entry is
respectfully requested.

Applicants amended claim 4 to properly depend from elected claims, as suggested by the
Examiner.

The Examiner rejected claims 1 and 4-6 under 35 USC 112, 1st paragraph for not
enabling an isolated polypeptide having a portion of SEQ ID NO:1 and VEGF antagonist
activity. Applicants respectfully disagree. However, in order to expedite prosecution,
Applicants have amended claim 1 to recite that the portion includes amino acids 22-44 of SEQ
ID NO:1.

The Examiner rejected claim 1 under 35 USC 102(b) as being anticipated by Fleurbaaj et
al. (WO/9606641), and claims 1 and 4-6 under 35 USC 103(a) as being obvious in view of
Fleurbaaj et al. It is the Examiner's position that Fleurbaaj et al. teaches an isolated